Observational study of treatment of epidermal growth factor receptor activating mutation positive(EGFRm+)advanced or recurrent non-small-cell lung cancer

Not Applicable

Completed

• Conditions: Advanced lung cancer

• Registration Number: JPRN-UMIN000010538
• Lead Sponsor: C-02 Executive committee

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-04-19
• Study Completion: 2014-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Exclusion Criteria

1.History of platinum-based adjuvant chemotherapy 2.Presence of other active malignancy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The time from RECIST-based PD to clinical PD with EGFR-TKI.

Secondary Outcome Measures

Name	Time	Method
1.Proportion of patients to whom EGFR-TKI was continued after radiological PD was judged according to RECIST to EGFR-TKI 1)with or without concomitant therapy 2)with concomitantly administered radiotherapy, surgery or chemotherapy 2.Propotion of patients in which flare developed after discontinuation of EGFR-TKI 3.Pattern of failure at the time of judgment as RECIST-based PD 4.Whole duration of treatment with EGFR-TKI 5.Survival after discontinuation of treatment with EGFR-TKI 6.Survival after RECIST-based PD to EGFR-TKI therapy was judged 7.Survival after clinical PD to EGFR-TKI therapy was judged 8.Reason of discontinuation of EGFR-TKI 9.Overall survival time